Sexual dysfunction after premenopausal stage I and II breast cancer: do androgens play a role?
BACKGROUND
Sexual dysfunction after breast cancer has been attributed to a variety of treatment associated and psychological factors. Data on the role of a treatment-induced decrease of testosterone for the development of sexual problems in breast cancer survivors have remained inconclusive. However, androgen metabolites constitute a more reliable measure for total androgen activity.


OBJECTIVE
To measure levels of total androgen activity in breast cancer patients and to investigate relevant predictors of sexual dysfunction after breast cancer.


METHODS
Twenty-nine patients with a premenopausal diagnosis of Stage I or II breast cancer and terminated adjuvant treatment, completed questionnaires on sexuality, quality of relationship, body image, and depression. In addition, blood samples were taken for the analysis of sex steroids.


METHODS
Female Sexual Function Index (FSFI), Relationship (PFB), Beck Depression Inventory, and European Organization for Research and Treatment of Cancer quality of life questionnaire. Analysis of dihydroepiandrosterone, dihydroepiandrosterone-sulfate, androstenedione, 17beta-diol, testosterone, dihydrotestosterone, androsterone, and ADT-G, 3-alpha-diol-3G, 3-alpha-diol-17G.


RESULTS
Low levels of sex steroids reflected the medication-induced postmenopausal status independent of the type of chemotherapy treatment. Sexual dysfunction was present in 68% of the study group. Women with a history of chemotherapy were more affected in all of the FSFI-domains. The only predictor for desire was quality of relationship, while chemotherapy was predictive for problems with arousal, lubrication, orgasm, and sexual pain. Sexual satisfaction and higher FSFI sum scores were predicted by better quality of relationship and no history of chemotherapy, together explaining 54.2% and 49.7% of the variance.


CONCLUSIONS
Sexual dysfunction after breast cancer is common and women should be informed properly at an early stage of treatment. Specific interventions have to be offered considering person-related preexisting factors and couples at risk should be supported in the transition to sexual life after breast cancer.
Alder
Judith
J
University Hospital Basel, Department Obstetrics and Gynecology, Basel, Switzerland. jalder@uhbs.ch
Zanetti
Rosanna
R
Wight
Edward
E
Urech
Corinne
C
Fink
Nadine
N
Bitzer
Johannes
J
D000328:Adult; D000728:Androgens / Q000097:blood*; D000738:Androsterone / Q000097:blood; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D013196:Dihydrotestosterone / Q000097:blood; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D007989:Libido / Q000502:physiology; D008875:Middle Aged; D009948:Orgasm / Q000502:physiology; D017697:Premenopause / Q000097:blood*; D012735:Sexual Dysfunction, Physiological / Q000097:blood* / Q000175:diagnosis / Q000523:psychology; D013739:Testosterone / Q000097:blood
D000728:Androgens; D013196:Dihydrotestosterone; D013739:Testosterone; D004958:Estradiol; D000738:Androsterone